Genocea Biosciences (GNCA) Misses Q1 EPS by 11c

Genocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.46), $0.11 worse than the analyst estimate of ($0.35).

Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2021.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• FuelCell Energy (FCEL) Misses Q3 EPS by 24c
• Netskope, Inc. (NTSK) Tops Q2 EPS by 4c, Offers Guidance